eNIOS was awarded the 1st prize of Pfizer’s accelerator Start4Health

eNIOS was awarded the 1st prize of Start4Health, an accelerator organized by Pfizer’s Center of Digital Innovation.

Start4Health focused on Digital Health and targeted startup companies that develop solutions that can tackle challenges of the health industry, improve the digital experience of patients and promote wellness through technology. eNIOS worked closely with the programme’s experts and presented its technology for acceleration of Precision Medicine, which aims to individualize therapeutic management in a broad spectrum of diseases.

We would like to thank the CDI team and partners involved in the realization of this exciteful programme and congratulate all finalist participants for their exciting and inspiring digital healthtech ventures.


e-NIOS is a partner of the international INNOCENT project, with the aim to develop an innovative multifunctional nano-pharmaceutical to overcome the low efficacy and frequent relapses in breast cancer treatment. The use of nano-based delivery systems, together with the benefits of a new generation of epi-drugs and the emergence of robust biomarker data, will help to advance personalized-targeted therapy and the efficacy of treatment for breast and other cancers. The proposed nano-drug will integrate the diagnostic and therapeutic functions within a single nanostructure.

A new paper is publicly accessible here: https://www.mdpi.com/2072-6694/12/12/3622/htm

BioInfoMiner elucidates the role of the early secretory pathway in SARS-CoV-2 infection


Here, we analyze and discuss the contribution of the molecular machines operating in the early secretory pathway in the biogenesis of SARS-CoV-2 and their relevance for potential antiviral targeting. The fact that these molecular machines are conserved throughout evolution, together with the redundancy and tissue specificity of their components, provides opportunities in the search for unique proteins essential for SARS-CoV-2 biology that could also be targeted with therapeutic objectives. Finally, we provide an overview of recent evidence implicating proteins of the early secretory pathway as potential antiviral targets with effective therapeutic applications.

The journeys of CoV-2 in the host cell. Coronavirus infection starts with the binding of the spike protein to cognate receptors. This drives conformational changes that promote fusion of the viral particle with the host cell’s plasma membrane. Once in the cytoplasm, viral particles are uncoated, and the viral RNA genome is translated, producing two polyproteins (pp1a and pp1ab). These polypeptides are proteolytically processed by host and viral proteases, generating nonstructural proteins (nsps). nsps assemble to form the replicase (R), which together with pp1a/pp1ab produces the replicase–polymerase complex. Replicase polymerase complex is responsible for the replication of the viral genome and for the production of subgenomic RNAs. The latter are translated to form structural proteins nucleocapsid (N), spike (S), membrane (M), and envelope (E). In addition to these genomic elements shared by other CoVs, the SARS-CoV-2 genome also contains eight ORFs coding for accessory proteins. Structural proteins are subjected to diverse posttranslational modifications in the ER and Golgi compartments, including disulfide bond and formation N- and O-glycosylation. Structural proteins concentrate in the ERGIC, where they assemble around the genome–nucleocapsid complexes. Mature virions are packed and budded in smooth-walled vesicles and then transported along downstream organelles of the exocytic pathway.

RA-map: a state-of-the-art interactive knowledge base for rheumatoid arthritis

RA-map is a fully annotated, expert validated, state-of-the-art knowledge base for RA in the form of a molecular map. BioInfoMiner was used for topological, functional and pharmacogenomic analysis.

The publication is accessible at:

Vidisha Singh, George D Kalliolias, Marek Ostaszewski, Maëva Veyssiere, Eleftherios Pilalis, Piotr Gawron, Alexander Mazein, Eric Bonnet, Elisabeth Petit-Teixeira, Anna Niarakis, RA-map: building a state-of-the-art interactive knowledge base for rheumatoid arthritis, Database, Volume 2020, 2020, baaa017, https://doi.org/10.1093/database/baaa017

New publication on bioinformatic analysis of phage display experiments

In this publication, we introduce PepSimili, an integrated workflow tool, which performs mapping of massive peptide repertoires on whole proteomes and delivers a streamlined, systems-level biological interpretation.


Find our new paper here.

The molecular mechanisms underlying inflammatory bowel diseases remain currently not completely understood, and therapeutic options are scarce.

Herein, we have identified that a normally endoplasmic reticulum resident protein, AGR2, exhibits tightly regulated secretion mechanisms that are perturbed in Crohn’s disease. We demonstrate that the extracellular release of AGR2 leads to the chemoattraction of monocytes, thereby suggesting extracellular AGR2’s pro‐inflammatory functions, that can be blocked using specific antibodies.

As a consequence, this discovery could represent an appealing therapeutic approach to attenuate the inflammatory burden in Crohn’s disease.

Join us at Bio-IT World 2019 Boston

e-NIOS is excited to participate in Bio-IT World, 16-18 April 2019, Boston. Join us at Seven Bridges’ booth #332 in the Exhibit Hall, for a demonstration of signature-based interpretation on the Seven Bridges Platform with BioInfoMiner!


Collaborative publication with DKFZ, ACCC and NHRF on Radiogenomics and Colorectal Cancer towards Precision Medicine

This is a new e-NIOS’ collaborative work on composite biomarker signatures, combining genomics with positron emission tomography (PET) measurements.

Online paper (open access)

The Athens Comprehensive Cancer Center (ACCC) was founded in 2017, in partnership with  the German Cancer Research Center (DKFZ) (Heidelberg, Germany) and aims to position itself as the first comprehensive cancer center in Greece based on innovative strategies for precision oncology.


Unlabelled Image

Seven Bridges & e-NIOS Partnership to Break the Biomarker Bottleneck



PR Newswire

Cambridge, Mass. and Athens, Greece., Sept 11, 2018. Seven Bridges, the leading biomedical data platform and analytics company, and e-NIOS, a biological knowledge discovery start-up, announced a strategic partnership towards data-driven discovery of biomarker signatures. Derivation of robust biomarkers from next generation sequencing and multi-omic data is currently a major bottleneck in precision medicine initiatives. This bottleneck continues to limit the transformation of genomic information into biomedical insights that will improve clinical outcomes through more efficient drug target discovery and more effective patient stratification.

Together, we are leveraging machine learning and physiology to improve and partially automate interpretation of potential biomarkers. Currently, interpretation is largely performed manually, relying on expert decisions. Human experts are both costly and inconsistent. Our partnership will develop efficient and standardized interpretation frameworks which harness the inherent complexity of molecular networks. This partnership has the potential to shift from listing all statistical correlations towards focusing on a smaller set of causal associations.

e-NIOS’ innovative technology enables unsupervised, intelligent translation of -omics data through BioInfoMiner, a cloud platform that resolves biological complexity and derives molecular signatures suitable for data-driven interpretation in different conditions, physiological states and datasets. Additionally, it allows the integration of different -omic layers (genomic, epigenomic, transcriptomic, proteomic, variants). BioInfoMiner can also drive discovery in studies related to plant and microbial systems.

According to e-NIOS’ co-founder Aristotelis Chatziioannou (CEO), “e-NIOS and Seven Bridges share the same vision for data-driven, streamlined computational genomics, integrating all steps from raw data to actionable biological interpretation. The Seven Bridges Platform is a valuable, high-performance cloud environment for the deployment of complex workflows and streamlined processing of massive, genomic datasets. Seven Bridges has been an excellent technological partner for our company as we work together to enable innovative, automated, data-driven biomarker industrial services and applications in the area of precision medicine.”
As Brandi Davis-Dusenbery, CEO of Seven Bridges, explained, “e-NIOS’ technology has the unique ability to combine biological network information with data-driven models. Here we bring together the technical and scientific strengths of both companies to provide a complete solution for the prediction of biomarker associations from raw data. Our strategic partnership supports Seven Bridges’ mission to connect the world’s biomedical information and rapidly transform it into actionable information.”

About Seven Bridges

Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development, and precision medicine. Thousands of researchers in government, biotech, and academia use Seven Bridges, including leading global pharmaceutical companies and national genomics projects such as the U.S. National Cancer Institute-funded Cancer Genomics Cloud, the Gabriella Miller Kids’ First Data Center, the Million Veteran Program, and the U.S. National Institutes of Health Data Commons Pilot. To find out more, contact us.

About e-NIOS

e-NIOS Applications P.C. is a spin-off company of the National Hellenic Research Foundation, founded by a multidisciplinary team with expertise in the fields of Bioinformatics, Genomics, Artificial Intelligence, Data Mining, Operational Research and Decision Support Systems. The company participates in many funded EU Horizon 2020 Research & Innovation networks and has developed sustainable international collaborations with partners such as the National University of Ireland, Galway, the French National Institute of Health and Medical Research (INSERM) the German Anticancer Institute Deutsches Krebsforschungszentrum  (DKFZ, Heidelberg) and many Universities and research groups across Europe. Research results obtained through e-NIOS technology have been published in high impact journals (EMBO Molecular Medicine, Cell Metabolism, FASEB, Scientific Reports and Nature Communications). e-NIOS recently filed a joint international patent with INSERM, France, entitled “Method of therapy selection for patients suffering from Glioblastoma”, exploiting results generated through BioInfoMiner. To find out more, contact us.



Meet us at the ECCB 2018 Conference

e-NIOS is excited to sponsor and participate in the 7th European Conference on Computational Biology, 8-12 September, 2018, Athens.

ECCB is the main computational biology event in Europe and will welcome scientists working in a variety of disciplines, including bioinformatics, computational biology, biology, medicine, and systems biology.

On Tuesday September 11, 2018 Eleftherios Pilalis, CTO, will present the BioInfominer platform for streamlined genomic interpretation at the Applications track.